公司资料
Vor Biopharma 股价、新闻与催化剂
- 股票代码:
- VOR
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
23.36 USD (+1.28%)
收盘价
最后更新: 2026年8月21日
740M USD
市值
股价为何变动
As of Aug 21, 2026, VOR closed up 1.28% at $23.36. No new same-company headline was identified in the current news window.
公司概览
Autoimmune B-Cell Therapy Company
Vor Bio is developing telitacicept for antibody-driven autoimmune diseases.
Telitacicept
Telitacicept is a recombinant fusion protein that inhibits both BAFF and APRIL, reducing survival signals for autoreactive B cells and plasma cells.
Global Phase 3 Programs
The UPSTREAM program is evaluating telitacicept in generalized myasthenia gravis and primary Sjögren’s disease.
未来催化剂
- Topline results from the Phase 3 UPSTREAM MG study are anticipated in the first half of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。